Sign in

You're signed outSign in or to get full access.

Shinichiro Ueda

Research Analyst at Goldman Sachs Group Inc.

Shinichiro Ueda is an Equity Analyst at Goldman Sachs specializing in the coverage of the Japanese pharmaceutical sector, with recent direct engagement in research on Takeda Pharmaceutical Co Ltd. He has contributed to earnings call research and questions, reflecting active involvement with major industry players, though public performance metrics such as TipRanks rankings, average returns, or formal analyst ratings are not available. Ueda's career at Goldman Sachs includes public-facing research participation as of 2024, but specific details regarding previous employers or the timeline of his professional advancement remain undisclosed. Currently, there is no verifiable information about securities licenses, FINRA registration, or other professional certifications attributed to Shinichiro Ueda.

Shinichiro Ueda's questions to TAKEDA PHARMACEUTICAL CO (TAK) leadership

Question · Q1 2025

Shinichiro Ueda from Goldman Sachs asked about Takeda's launch preparations for oviporexant, specifically regarding the commercial team structure and the use of digital technologies to improve patient diagnosis for narcolepsy type 1.

Answer

U.S. Business Unit President Julie Kim confirmed that Takeda is actively preparing for the launch, with medical teams already educating in the field. She highlighted a focus on using multiple digital avenues to support and unlock bottlenecks in diagnosis, particularly through sleep centers, with more details to be shared closer to launch.

Ask follow-up questions

Fintool

Fintool can predict TAKEDA PHARMACEUTICAL CO logo TAK's earnings beat/miss a week before the call